184 related articles for article (PubMed ID: 35292180)
21. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
Gadducci A; Cosio S; Lippolis PV
Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
[TBL] [Abstract][Full Text] [Related]
22. Developing a hyperthermic intraperitoneal chemotherapy (HIPEC) gynecologic oncology program: a Canadian experience.
Neveu J; Tremblay E; Mercier F; Garneau S; Cormier B
Int J Gynecol Cancer; 2023 Dec; 33(12):1957-1965. PubMed ID: 38011988
[TBL] [Abstract][Full Text] [Related]
23. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.
Vos LMC; Aronson SL; van Driel WJ; Huitema ADR; Schagen van Leeuwen JH; Lok CAR; Sonke GS
Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():86-102. PubMed ID: 34565676
[TBL] [Abstract][Full Text] [Related]
24. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
Mendivil AA; Rettenmaier MA; Abaid LN; Brown JV; Mori KM; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2017 Aug; 80(2):405-410. PubMed ID: 28669065
[TBL] [Abstract][Full Text] [Related]
25. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
de Bree E; Michelakis D
Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
[TBL] [Abstract][Full Text] [Related]
26. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
Kim SI; Kim JH; Lee S; Cho H; van Driel WJ; Sonke GS; Bristow RE; Park SY; Fotopoulou C; Lim MC
Gynecol Oncol; 2022 Dec; 167(3):547-556. PubMed ID: 36273925
[TBL] [Abstract][Full Text] [Related]
27. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer.
Kim SI; Kim JW
ESMO Open; 2021 Jun; 6(3):100149. PubMed ID: 33984680
[TBL] [Abstract][Full Text] [Related]
28. Role of Hyperthermic Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery as Consolidation Therapy for Advanced Epithelial Ovarian Cancer.
Frankinet L; Bhatt A; Alcazer V; Classe JM; Bereder JM; Meeus P; Pomel C; Mithieux F; Abboud K; Wermert R; Lavoue V; Marchal F; Glehen O; Bakrin N
Ann Surg Oncol; 2023 Jun; 30(6):3287-3299. PubMed ID: 36820940
[TBL] [Abstract][Full Text] [Related]
29. Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma.
Rettenmaier MA; Mendivil AA; Gray CM; Chapman AP; Stone MK; Tinnerman EJ; Goldstein BH
Int J Hyperthermia; 2015 Jun; 31(4):396-402. PubMed ID: 25707816
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN; Kieffer JM; K Sikorska ; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham MAPC; Aalbers AG; Verwaal VJ; Van de Vijver KK; Sonke GS; van Driel WJ; Aaronson NK
Eur J Surg Oncol; 2021 Jan; 47(1):101-107. PubMed ID: 31128948
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: Indications for hyperthermic intraperitoneal chemoperfusion therapy.
Tu Y; Tian Y; Wu Y; Cui S
Oncol Lett; 2018 Jun; 15(6):9385-9391. PubMed ID: 29946371
[TBL] [Abstract][Full Text] [Related]
32. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
[TBL] [Abstract][Full Text] [Related]
33. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
[TBL] [Abstract][Full Text] [Related]
34. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Schwameis R; Chiva L; Harter P
Int J Gynecol Cancer; 2022 Apr; 32(4):578. PubMed ID: 35121632
[No Abstract] [Full Text] [Related]
35. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.
Polom K; Roviello G; Generali D; Marano L; Petrioli R; Marsili S; Caputo E; Marrelli D; Roviello F
Int J Hyperthermia; 2016 May; 32(3):298-310. PubMed ID: 26984715
[TBL] [Abstract][Full Text] [Related]
36. The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines.
Helderman RFCPA; Löke DR; Verhoeff J; Rodermond HM; van Bochove GGW; Boon M; van Kesteren S; Garcia Vallejo JJ; Kok HP; Tanis PJ; Franken NAP; Crezee J; Oei AL
Cells; 2020 Jul; 9(8):. PubMed ID: 32722384
[TBL] [Abstract][Full Text] [Related]
37. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Argenta PA; Sueblinvong T; Geller MA; Jonson AL; Downs LS; Carson LF; Ivy JJ; Judson PL
Gynecol Oncol; 2013 Apr; 129(1):81-5. PubMed ID: 23352917
[TBL] [Abstract][Full Text] [Related]
38. The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer.
Brennan DJ; Driel WJV; Zivanovic O
Int J Gynecol Cancer; 2023 May; 33(5):851-852. PubMed ID: 36898700
[No Abstract] [Full Text] [Related]
39. Paclitaxel increases sensitivity of SKOV3 cells to hyperthermia by inhibiting heat shock protein 27.
Kong XX; Jiang S; Liu T; Liu GF; Dong M
Biomed Pharmacother; 2020 Dec; 132():110907. PubMed ID: 33113434
[TBL] [Abstract][Full Text] [Related]
40. Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study.
Durán-Martínez M; Gómez-Dueñas G; Rodriguez-Ortíz L; Sanchez-Hidalgo JM; Gordón-Suárez A; Casado-Adam Á; Rufián-Peña S; Valenzuela-Molina F; Rufián-Andujar B; Vázquez-Borrego MC; Romero-Ruiz A; Briceño-Delgado J; Arjona-Sánchez Á
Surg Endosc; 2024 Jan; 38(1):66-74. PubMed ID: 37903884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
